Pooled Analysis of the Efficacy, Safety, and Health Outcomes Following 48 Weeks of Long-acting Cabotegravir and Rilpivirine Maintenance Therapy for HIV-1 Infection in Phase 3 ATLAS and FLAIR Studies: Sub-Analysis in Asian Populations